SELLAS Life Sciences (NASDAQ: SLS) entered the second half of 2026 with a substantial cash position that could fund operations for over four years at its current burn rate. However, the presence of a $150 million at-the-market (ATM) equity facility continues to influence investor sentiment, reminding the market that dilution remains a tool management can deploy at its discretion.
The company reported $138.3 million in cash and equivalents as of June 30, while its latest Form 10-Q revealed operating cash outflows of $16.4 million for the first six months of the year. This translates to a mechanical runway of roughly 50.5 months, or 4.2 years, assuming the burn rate remains unchanged. That calculation, however, is a TS2 analysis, not official company guidance. SELLAS only commits that its cash will fund planned operations for at least 12 months from the issuance of its financial statements.
Spending Trends and the Path to Profitability
The comfort of a long runway is tempered by rising expenses. First-half R&D costs climbed to $11.4 million from $7.1 million a year earlier, while G&A expenses rose to $8.5 million from $5.9 million. Management attributes the R&D increase to manufacturing, trial activities, and regulatory consulting ahead of a potential biologics license application for galinpepimut-S (GPS). If the drug succeeds in trials, spending could escalate well beyond the historical burn rate, making the cash cushion less generous than it appears.
Another key point: the balance sheet strength is not organic. During the first half, SELLAS generated $82.9 million from the exercise of 48.8 million warrants, pushing cash from $71.8 million at year-end to the current level. Financing cash flow, not product revenue, built the war chest. The company remains a clinical-stage biotech reliant on capital markets.
The 0 Million ATM Facility
The ATM agreement, established in March, allows SELLAS to sell common shares through TD Cowen at its discretion. As of the 10-Q filing, no shares had been sold under the facility. This is optional capacity, not a scheduled offering, and it could be strategically valuable for funding manufacturing, regulatory work, or expanding the SLS009 program without waiting for cash to run low.
At the September 11 closing price of $11.545, the full $150 million would represent approximately 13.0 million shares, or 6.4% of the 201.9 million shares outstanding as of August 10. This is a sensitivity analysis, not a forecast. Actual issuance could be smaller, larger if the stock falls, or unnecessary in the near term. Raising capital at higher share prices is prudent insurance, especially compared to financing after disappointing data.
Despite the cash, it supports only a small fraction of the company's valuation. At the same closing price, SELLAS's market cap is near $2.33 billion. June cash equates to about $0.68 per share, or 5.9% of that figure. Investors are paying for clinical success, not the balance sheet.
Two Clinical Catalysts Ahead
The first catalyst is the Phase 3 REGAL study of GPS in acute myeloid leukemia (AML). SELLAS plans to start the final analysis after the 80th prespecified event, followed by database lock, blinded review, statistical analysis, and unblinding. As of May 11, 78 events had occurred; the August 11 update said the trial was approaching the threshold but had not yet reached it. A slower event rate does not indicate efficacy because the data remains blinded.
The second is SLS009 (tambiciclib). SELLAS has enrolled 28 patients in an 80-patient Phase 2 first-line AML study and targets topline data in the fourth quarter. The federal ClinicalTrials.gov record, last updated July 8, lists the broader SLS009 study as recruiting, with estimated primary completion in December 2026.
Market Implications
These readouts will shape the financing equation. Positive data could lift the stock, improve partnership prospects, and make any ATM use less dilutive. Weak or ambiguous results could compress the valuation while spending continues. The cash cushion provides negotiating time, but it does not eliminate the clinical risk that determines the value of that time.
SLS shares closed at $11.545 on September 11, down 14.4% on volume of about 14.6 million shares. For investors looking beyond the volatile tape, the next signal is whether the ATM share count begins to move before the two clinical programs deliver their evidence.
